JPRN-UMIN000038636尚未招募未知
Clinical outcome of beta3 agonists, Mirabegron and Vibegron sequential therapy for overactive bladder(OAB) - OAB beta3 agonists sequential therapy
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 100years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Urgency due to bladder infection,urinary malignancies 2) patients who is not available for beta3 agonist treatment 3) deny attending this clinical research
研究者
相似试验
已完成
不适用
Effect of Mirabegron (beta 3-adrenergic receptor agonist) on overactive bladder patients : a functional brain imaging studyOveractive bladderJPRN-UMIN000014150Hokkaido University Graduate School of Medicine10
Unknown
1 期
Beta 3 Agonists in Treatment of Non-neurogenic Voiding Dysfunction in ChildrenVoiding DisordersOveractive BladderNCT05240456Mansoura University70
尚未招募
不适用
The clinical study of beta 3-agonist (Betanis) for lower urinary tract symptoms mainly for overactive bladderlower urinary tract symptoms (overactive bladder)JPRN-UMIN000008084Dept. of Urology, Kyoto University Hospital100
已完成
不适用
Mirabegron,beta-3 adrenoceptor agonist, Evaluate on efficacy, tolerability and QOL,in female overactive bladder with nocturiaJPRN-UMIN000012804-QOL Study Group100
招募中
3 期
Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus SolifenacinOveractive Bladder SyndromeNCT04023253Far Eastern Memorial Hospital120